Overview
Canada cannabis firm's Q4 revenue beat analyst expectations
Company renewed share buyback program for up to $10 mln USD during the year
Outlook
TerrAscend says it expects sustainable growth and shareholder value in 2026 and beyond
TerrAscend plans to focus M&A strategy on accretive transactions aligned with strategic goals
Result Drivers
WHOLESALE AND PRODUCT PERFORMANCE - Co cited sequential increases in both retail and wholesale revenue, with branded products ranking highly in Maryland and Pennsylvania
Company press release: ID:nGNX62XBPy
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$66.10 mln
$64.68 mln (4 Analysts)
Q4 Gross Margin
52.1%
Q4 Net Income from Cont. Ops
-$500,000
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Terrascend Corp is C$2.00, about 119.8% above its March 11 closing price of C$0.91
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)